Journal for ImmunoTherapy of Cancer (Nov 2023)
609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Nov 2023)